Found: 33
Select item for more details and to access through your institution.
Capture Hi-C identifies putative target genes at 33 breast cancer risk loci.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-03411-9
- By:
- Publication type:
- Article
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-01864-y
- By:
- Publication type:
- Article
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
- Published in:
- Nature Communications, 2016, v. 7, n. 11, p. 13294, doi. 10.1038/ncomms13294
- By:
- Publication type:
- Article
ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1.
- Published in:
- PLoS Genetics, 2011, v. 7, n. 4, p. 1, doi. 10.1371/journal.pgen.1001382
- By:
- Publication type:
- Article
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 313, p. 1, doi. 10.1126/scitranslmed.aac7551
- By:
- Publication type:
- Article
Enhancing endocrine response with novel targeted therapies.
- Published in:
- Cancer (0008543X), 2008, v. 112, p. 710, doi. 10.1002/cncr.23190
- By:
- Publication type:
- Article
Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
- Published in:
- 2008
- By:
- Publication type:
- journal article
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
- Published in:
- Breast Cancer Research, 2015, v. 17, n. 1, p. 1, doi. 10.1186/s13058-015-0532-0
- By:
- Publication type:
- Article
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Identification of chemokine receptors as potential modulators of endocrine resistance in estrogen receptor positive breast cancers.
- Published in:
- Breast Cancer Research, 2014, v. 16, n. 5, p. 1, doi. 10.1186/s13058-014-0447-1
- By:
- Publication type:
- Article
Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Relationship of PIK3CA mutation and pathway activity with anti-proliferative response to aromatase inhibition.
- Published in:
- Breast Cancer Research, 2014, v. 16, n. 3, p. 1, doi. 10.1186/bcr3683
- By:
- Publication type:
- Article
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
- Published in:
- Breast Cancer Research, 2012, v. 14, n. 5, p. 3330, doi. 10.1186/bcr3330
- By:
- Publication type:
- Article
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
- Published in:
- 2012
- By:
- Publication type:
- journal article
The role of caveolin-1 in human breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 131, n. 1, p. 1, doi. 10.1007/s10549-011-1751-4
- By:
- Publication type:
- Article
Non-existence of caveolin-1 gene mutations in human breast cancer.
- Published in:
- 2012
- By:
- Publication type:
- Report
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 128, n. 2, p. 357, doi. 10.1007/s10549-010-1122-6
- By:
- Publication type:
- Article
Synergistic activity of letrozole and sorafenib on breast cancer cells.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 124, n. 1, p. 79, doi. 10.1007/s10549-009-0714-5
- By:
- Publication type:
- Article
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2010, v. 123, n. 3, p. 829, doi. 10.1007/s10549-010-1100-z
- By:
- Publication type:
- Article
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00483-1
- By:
- Publication type:
- Article
Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?
- Published in:
- Clinical Breast Cancer, 2010, v. 10, p. S79, doi. 10.3816/CBC.2010.s.016
- By:
- Publication type:
- Article
Biomarkers for the clinical management of breast cancer: International perspective.
- Published in:
- International Journal of Cancer, 2013, v. 133, n. 1, p. 1, doi. 10.1002/ijc.27997
- By:
- Publication type:
- Article
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
- Published in:
- PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0157397
- By:
- Publication type:
- Article
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article